Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of RAY1225 injection in type 2 diabetes mellitus
CTR20240361Phase 2Completed
- Sponsor
- Raynovent Biotech
- Start
- Feb 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of RAY1225 in type 2 diabetes mellitus (T2DM), sponsored by Raynovent Biotech. Started Feb 2024; status: completed.
02
Drugs
RAY1225
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20240361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240361.